OPKO Health to Present at UBS 2007 Global Life Sciences Conference
MIAMI, Sept. 18 /PRNewswire-FirstCall/ -- OPKO Health Inc. (Amex: OPK) today announced that it will present at the UBS 2007 Global Life Sciences Conference on Tuesday, September 25, 2007 at 11:30 am EDT. The conference will be held at the Grand Hyatt New York in New York City.
OPKO senior management will provide a review of recent corporate developments.
The audio portion of the company's presentation will be webcast live. It can be accessed at the Investors Relations section of the OPKO Health website at www.opko.com. An archived version of the webcast will be available for 30 days beginning three hours after the start of the presentation. The live and archived audio webcast can also be accessed at the UBS website at http://events.streamx.us/us/event/eventdetails.aspx?id=ubs20070924.
About OPKO Health, Inc.
Miami-based OPKO is a specialty healthcare company. Its lead investigational drug, the pioneering gene silencing agent bevasiranib, has entered a pivotal Phase 3 trial after successfully completing Phase 2 trials for the treatment of wet age-related macular degeneration and macular degeneration. OPKO is developing a preclinical pipeline of novel agents for ophthalmic diseases, and it also intends to market diagnostic systems that complement its therapeutic products. The company recently announced it has entered into an agreement to acquire Ophthalmic Technologies, Inc. (OTI), a provider of innovative patient imaging systems to eye care professionals worldwide. For more information visit www.opko.com.
This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding our product development efforts, our ability to develop a preclinical pipeline of novel agents for ophthalmic diseases, our ability to market diagnostic systems that complement our therapeutic products, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, including the risks that enrollment of patients for the Phase 3 clinical trial for bevasiranib, may not be successful, that the Phase 3 clinical trial itself may not be completed on a timely basis or at all, that any of our compounds under development, including bevasiranib, may fail, may not achieve the expected results or effectiveness and may not generate data that would support the approval or marketing of products for the indications being studied or for other indications. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward- looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.
Contacts: Media:
Corporate: GendeLLindheim BioCom Partners
Steven D. Rubin Barbara Lindheim
305 575-6015 212 918-4650
SOURCE OPKO Health Inc.
Released September 18, 2007